Extensive literature exists on the beneficial effects of synthetic PPARγ agonists, and in particular pioglitazone, in limiting insulin resistance, protecting pancreatic β cell function and our own data suggest a protective effect on nephropathy [16–20]. This evidence concerns the gene PPARG and Insulin resistance.